Daniil Gataulin
Stock Analyst at Chardan Capital
(4.78)
# 94
Out of 5,163 analysts
128
Total ratings
62.07%
Success rate
41.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniil Gataulin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Maintains: Buy | $9 → $11 | $5.03 | +118.69% | 4 | Mar 12, 2026 | |
| QURE uniQure | Maintains: Buy | $16 → $31 | $15.53 | +99.61% | 13 | Mar 9, 2026 | |
| OCGN Ocugen | Maintains: Buy | $7 | $2.48 | +182.26% | 16 | Mar 5, 2026 | |
| CRVO CervoMed | Maintains: Buy | $15 | $4.25 | +252.94% | 8 | Mar 5, 2026 | |
| EYPT EyePoint | Maintains: Buy | $27 → $29 | $13.20 | +119.70% | 13 | Mar 4, 2026 | |
| OTLK Outlook Therapeutics | Maintains: Neutral | $1 | $0.39 | +153.81% | 12 | Feb 18, 2026 | |
| OCUL Ocular Therapeutix | Maintains: Buy | $21 | $8.76 | +139.73% | 5 | Feb 18, 2026 | |
| RGNX REGENXBIO | Maintains: Buy | $52 → $50 | $8.57 | +483.43% | 16 | Feb 10, 2026 | |
| ANNX Annexon | Initiates: Buy | $16 | $5.66 | +182.69% | 1 | Dec 23, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Buy | $19 | $8.72 | +117.89% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $61 | $26.74 | +128.12% | 7 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 | $23.19 | -39.63% | 4 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $6.17 | +62.07% | 3 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 | $7.39 | +373.61% | 7 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 | $25.43 | +100.55% | 9 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 | $1.05 | +280.95% | 8 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2,200 | $4.10 | +53,558.54% | 1 | Mar 7, 2024 |
Opus Genetics
Mar 12, 2026
Maintains: Buy
Price Target: $9 → $11
Current: $5.03
Upside: +118.69%
uniQure
Mar 9, 2026
Maintains: Buy
Price Target: $16 → $31
Current: $15.53
Upside: +99.61%
Ocugen
Mar 5, 2026
Maintains: Buy
Price Target: $7
Current: $2.48
Upside: +182.26%
CervoMed
Mar 5, 2026
Maintains: Buy
Price Target: $15
Current: $4.25
Upside: +252.94%
EyePoint
Mar 4, 2026
Maintains: Buy
Price Target: $27 → $29
Current: $13.20
Upside: +119.70%
Outlook Therapeutics
Feb 18, 2026
Maintains: Neutral
Price Target: $1
Current: $0.39
Upside: +153.81%
Ocular Therapeutix
Feb 18, 2026
Maintains: Buy
Price Target: $21
Current: $8.76
Upside: +139.73%
REGENXBIO
Feb 10, 2026
Maintains: Buy
Price Target: $52 → $50
Current: $8.57
Upside: +483.43%
Annexon
Dec 23, 2025
Initiates: Buy
Price Target: $16
Current: $5.66
Upside: +182.69%
Kalaris Therapeutics
Dec 23, 2025
Initiates: Buy
Price Target: $19
Current: $8.72
Upside: +117.89%
Nov 17, 2025
Maintains: Buy
Price Target: $61
Current: $26.74
Upside: +128.12%
Nov 17, 2025
Maintains: Neutral
Price Target: $14
Current: $23.19
Upside: -39.63%
Nov 14, 2025
Maintains: Buy
Price Target: $10
Current: $6.17
Upside: +62.07%
Nov 14, 2025
Maintains: Buy
Price Target: $35
Current: $7.39
Upside: +373.61%
Nov 11, 2025
Maintains: Buy
Price Target: $51
Current: $25.43
Upside: +100.55%
Aug 8, 2025
Maintains: Buy
Price Target: $4
Current: $1.05
Upside: +280.95%
Mar 7, 2024
Maintains: Buy
Price Target: $2,200
Current: $4.10
Upside: +53,558.54%